Artivion chief commercial officer sells $64,938 of stock

John E. Davis, the Chief Commercial Officer of Artivion, Inc. (NYSE:AORT), a nearly $1 billion market cap medical device company, recently disclosed a sale of company stock. According to the SEC filing, Davis sold 2,618 shares of Artivion common stock on March 6, 2025, at an average price of $24.8047 per share, totaling approximately $64,938. InvestingPro data shows the stock currently trades at $23.50, with analysts setting price targets between $30 and $35.

This transaction occurred as part of a "sell to cover" move to satisfy tax withholding obligations following the vesting of performance stock units. This sale was not a discretionary transaction but was necessary to cover these obligations. According to InvestingPro’s analysis, the company maintains a "GOOD" overall financial health score, with liquid assets exceeding short-term obligations by a ratio of 4.34x.

Following this sale, Davis holds 207,968 shares of Artivion common stock. Additionally, Davis acquired 25,654 shares at no cost, as part of a performance stock unit grant, bringing his total holdings to 210,586 shares. The stock has shown significant volatility, with a beta of 1.79, and has delivered a 20.78% return over the past year despite recent weakness. Discover more insights about AORT and access detailed analysis in the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, Artivion Inc. reported its fourth-quarter 2024 earnings with revenues of $97.3 million, falling short of the forecasted $100.82 million due to a cybersecurity incident that impacted sales by approximately $4.5 million. Despite this, the company’s adjusted EBITDA surpassed expectations, reaching $17.6 million against the anticipated $17 million. Artivion’s full-year 2024 revenue totaled $388.5 million, slightly below the guidance range of $389 million to $396 million. Looking forward, Artivion anticipates 2025 revenues between $420 million and $435 million, with an adjusted EBITDA forecast of $83 million to $91 million, aligning with previous estimates. Analysts from Stifel, Needham, and JMP Securities have made adjustments to their outlooks, with Stifel lowering the price target to $30 while maintaining a Buy rating, Needham reducing the target to $32 with a Buy rating, and JMP reaffirming a $33 target. The cybersecurity breach, disclosed in December, has continued to affect operations, but Artivion expects a recovery over the course of the year. Additionally, the company is focused on new product launches and regulatory approvals to drive future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.